ONCOCYTE CORP (OCX) Stock Fundamental Analysis
NASDAQ:OCX - Nasdaq - US68235C2061 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to OCX. OCX was compared to 561 industry peers in the Biotechnology industry. OCX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, OCX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
OCX had negative earnings in the past year.
OCX had a negative operating cash flow in the past year.
OCX had negative earnings in each of the past 5 years.
In the past 5 years OCX always reported negative operating cash flow.
1.2 Ratios
OCX has a worse Return On Assets (-173.67%) than 86.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -173.67% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 31.74%, OCX is in the better half of the industry, outperforming 73.62% of the companies in the same industry.
In the last couple of years the Gross Margin of OCX has declined.
The Profit Margin and Operating Margin are not available for OCX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.74% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
2. Health
2.1 Basic Checks
OCX does not have a ROIC to compare to the WACC, probably because it is not profitable.
OCX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for OCX has been increased compared to 5 years ago.
The debt/assets ratio for OCX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -14.32, we must say that OCX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.32, OCX is doing worse than 80.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.32 |
ROIC/WACCN/A
WACC10.06%
2.3 Liquidity
OCX has a Current Ratio of 1.62. This is a normal value and indicates that OCX is financially healthy and should not expect problems in meeting its short term obligations.
OCX has a worse Current ratio (1.62) than 80.93% of its industry peers.
A Quick Ratio of 1.56 indicates that OCX should not have too much problems paying its short term obligations.
OCX's Quick ratio of 1.56 is on the low side compared to the rest of the industry. OCX is outperformed by 80.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 31.19% over the past year.
The Revenue has grown by 25.15% in the past year. This is a very strong growth!
Measured over the past years, OCX shows a decrease in Revenue. The Revenue has been decreasing by -5.09% on average per year.
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
Revenue 1Y (TTM)25.15%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%
3.2 Future
The Earnings Per Share is expected to grow by 21.86% on average over the next years. This is a very strong growth
Based on estimates for the next years, OCX will show a very strong growth in Revenue. The Revenue will grow by 197.76% on average per year.
EPS Next Y78.88%
EPS Next 2Y33.89%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue Next Year194.85%
Revenue Next 2Y176.9%
Revenue Next 3Y197.76%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for OCX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
OCX's earnings are expected to grow with 21.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.89%
EPS Next 3Y21.86%
5. Dividend
5.1 Amount
OCX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:OCX (5/23/2025, 8:43:23 PM)
3.37
-0.07 (-2.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners66.6%
Inst Owner Change91.22%
Ins Owners1.25%
Ins Owner Change19.59%
Market Cap96.38M
Analysts75
Price Target4.59 (36.2%)
Short Float %1.47%
Short Ratio4.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-234.86%
Min EPS beat(2)-347.17%
Max EPS beat(2)-122.54%
EPS beat(4)1
Avg EPS beat(4)-125.22%
Min EPS beat(4)-347.17%
Max EPS beat(4)36.24%
EPS beat(8)4
Avg EPS beat(8)-53.13%
EPS beat(12)7
Avg EPS beat(12)-55.38%
EPS beat(16)9
Avg EPS beat(16)-40.9%
Revenue beat(2)1
Avg Revenue beat(2)664.11%
Min Revenue beat(2)-43.07%
Max Revenue beat(2)1371.29%
Revenue beat(4)1
Avg Revenue beat(4)302.58%
Min Revenue beat(4)-67.67%
Max Revenue beat(4)1371.29%
Revenue beat(8)3
Avg Revenue beat(8)156.97%
Revenue beat(12)3
Avg Revenue beat(12)75.4%
Revenue beat(16)5
Avg Revenue beat(16)48.03%
PT rev (1m)1.89%
PT rev (3m)9.09%
EPS NQ rev (1m)7.8%
EPS NQ rev (3m)43.82%
EPS NY rev (1m)13.92%
EPS NY rev (3m)45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.03%
Revenue NY rev (1m)44%
Revenue NY rev (3m)42.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 51.24 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.53
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.07
BVpS-0.43
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -173.67% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.74% | ||
| FCFM | N/A |
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 32.99% | ||
| Cap/Sales | 27.43% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | -14.32 |
F-Score4
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)44.29%
Cap/Depr(5y)100.36%
Cap/Sales(3y)166.07%
Cap/Sales(5y)140.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
EPS Next Y78.88%
EPS Next 2Y33.89%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue 1Y (TTM)25.15%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%
Revenue Next Year194.85%
Revenue Next 2Y176.9%
Revenue Next 3Y197.76%
Revenue Next 5YN/A
EBIT growth 1Y-14.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.85%
EBIT Next 3Y11.26%
EBIT Next 5YN/A
FCF growth 1Y10.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.2%
OCF growth 3YN/A
OCF growth 5YN/A